Evidence map›Paper›PMID 38746061›Full record

ArticleVaccine: X2024

Presenting clinical symptoms of post-COVID-19 breakthrough infection: Predictors of mortality in a Middle Eastern population.

Asma S Albtoosh, Randa Farah, Khaled Al Oweidat, Osama Mohammad Hussein, Abdullah Ahmad Obeid, Haitham Mounir Hamila, Mousa Nizar Mousa Radwan, Radi Feras Ahmad, Hosam Marwan Masadeh, Abdalla Ibrahim Hammad and 6 more

Abstract read
In one paragraph

Article in Vaccine: X, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Asma S AlbtooshDepartment of Respiratory and Sleep Medicine, Department of Internal Medicine, School of Medicine, The University of Jordan, Amman, Jordan.
Randa FarahDepartment of Internal Medicine, School of Medicine, The University of Jordan, Amman, Jordan.
Khaled Al OweidatDepartment of Respiratory and Sleep Medicine, Department of Internal Medicine, School of Medicine, The University of Jordan, Amman, Jordan.
Osama Mohammad HusseinSchool of Medicine, The University of Jordan, Amman 11942, Jordan.
Abdullah Ahmad ObeidRespiratory and Sleep Medicine, Al Basheer Hospital, Ministry of Health, Jordan.
Haitham Mounir HamilaSchool of Medicine, The University of Jordan, Amman 11942, Jordan.
Mousa Nizar Mousa RadwanSchool of Medicine, The University of Jordan, Amman 11942, Jordan.
Radi Feras AhmadSchool of Medicine, The University of Jordan, Amman 11942, Jordan.
Hosam Marwan MasadehSchool of Medicine, The University of Jordan, Amman 11942, Jordan.
Abdalla Ibrahim HammadSchool of Medicine, The University of Jordan, Amman 11942, Jordan.
Ayman Mohammed MuslehSchool of Medicine, The University of Jordan, Amman 11942, Jordan.
Amal Ayman FakhourySchool of Medicine, The University of Jordan, Amman 11942, Jordan.
Farah Mahmoud DisiSchool of Medicine, The University of Jordan, Amman 11942, Jordan.
Yakoub Y Sh JoudahSchool of Medicine, The University of Jordan, Amman 11942, Jordan.
Nathir ObeidatDepartment of Respiratory and Sleep Medicine, Department of Internal Medicine, School of Medicine, The University of Jordan, Amman, Jordan.
Keira P MasonDepartment of Anesthesia, Boston Children's Hospital, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Breakthrough COVID-19 infections are common following immunisation with various types of vaccines. The patterns of infections have not been well established. We aimed to analyse the signs and symptoms of post vaccination infections in addition to the need for hospital admission, ER visit and supplemental oxygen in relation to age and gender. Methods: A cross-sectional cohort study was conducted in JUH from March 2021 to August 2022, we interviewed 1479 individuals who are >15 years of age and got a breakthrough infection. The statistical analysis was performed using STATA statistical software. Results: Out of the 1479 cases, 50.2 % and 69.4 % were females and less than 45 years of age respectively. Symptoms of cough, fever and headache were reported by nearly 50 % of the patients, while one-third complained of dyspnoea. We found that participants older than 45 years had worse clinical outcomes ( Conclusion: This study indicates that despite more severe symptoms reported in younger patients, the major clinical outcomes were worse among older patients, which makes age a major risk for poor outcomes regardless of symptoms. Thus, older people should be evaluated carefully when presenting with mild symptoms of COVID-19 breakthrough infection. The study also confirms that there is no difference in the incidence of COVID-19 breakthrough infections between males and females. Prospective studies are needed to risk stratify COVID-19 breakthrough infections, which should take into account variants of the virus and comorbidities.

Indexed as

COVID-19OutcomeSymptomsVaccine breakthrough

Identifiers

PMID38746061
PMCPMC11091517

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.